BCIQ Profiles

Company Profile ReportTarget Profile Report
DIST_0617_JCI142116

Combining CD51-TGFβ axis inhibition with NK cell therapy for glioblastoma

Jul 2, 2021 | 9:10 PM GMT

DISEASE CATEGORY: Cancer

INDICATION: Brain cancer

Targeting TGFβ activation mediated via the

Read the full 255 word article

How to gain access

Continue reading with a
two-week free trial.